Dark

PLX
Protalix BioTherapeutics, Inc. Common Stock
stock NYSEAMERICAN

At Close

Jul 10, 2025 3:59:30 PM EDT

1.47USD-4.248%(-0.07)674,776

1.45Bid 1.48Ask 0.03Spread

Pre-market

Jul 10, 2025 8:49:30 AM EDT

1.50USD-1.961%(-0.03)350

After-hours

Jul 10, 2025 4:00:30 PM EDT

1.48USD+1.024%(+0.02)122

OverviewOptionsHistoricalExchangesShortsNews

Dec 22, 2021

07:00AM EST Protalix :looks Forward With Anticipation To Continuing Progress In Advancing Potential Good Alternative For Fabry RTTNews

06:53AM EST Protalix BioTherapeutics Issues 2021 Letter To Stockholders Benzinga

Nov 15, 2021

02:07PM EST Watching Protalix BioTherapeutics; Zacks Small-Cap Research Issues $11 Valuation Benzinga

11:07AM EST Earnings Scheduled For November 15, 2021 Benzinga

10:51AM EST Protalix BioTherapeutics Q3 EPS $(0.09) Up From $(0.14) YoY, Sales $12.05M Up From $10.79M YoY Benzinga

10:37AM EST The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More Benzinga

06:57AM EST Protalix BioTherapeutics Q3 Net Loss $4.2 Mln, Or $0.09/shr Vs Net Loss Of $4.4 Mln Or $0.14/shr Prior Year RTTNews

06:50AM EST Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and PR Newswire

Nov 8, 2021

06:50AM EST Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and PR Newswire

Oct 20, 2021

08:11AM EDT PLX: Type A Meeting Provides Clarity Benzinga

Oct 15, 2021

08:41AM EDT Protalix, Chiesi Global Rare Diseases Announce Final Dosing Of Last Patient In Phase 3 BALANCE Trial Of PRX-102 RTTNews

08:39AM EDT Protalix Biotherapeutics And Chiesi Global Rare Diseases Announce Final Dosing Of Last Patient In Phase III BALANCE Clinical Trial PRX-102 For Treatment Of Fabry Disease Benzinga

08:38AM EDT of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease PR Newswire

Oct 11, 2021

07:28AM EDT Protalix BioTherapeutics Inc. (PLX) and Chiesi Global Rare Diseases said, in an update on pegunigalsidase alfa or PRX-102 for the treatment of Fabry Disease, that they are encouraged by productive discussion with the U.S. Food and Drug Administration, which the companies believe provides a pathway to resubmit the PRX-102 Biologics License Application. RTTNews

06:51AM EDT Protalix Biotherapeutics And Chiesi Global Rare Diseases Provide Regulatory Update On PRX-102 For The Treatment Of Fabry Disease Benzinga

06:51AM EDT Protalix Biotherapeutics And Chiesi Global Rare Diseases Provide Regulatory Update On PRX-102 For Fabry Disease RTTNews

06:50AM EDT Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory PR Newswire

Aug 26, 2021

06:52AM EDT Protalix BioTherapeutics Announces Closing Of 7.50% Senior Secured Convertible Notes Due 2021 Exchange RTTNews

06:51AM EDT Protalix BioTherapeutics Announces Closing of Private Note Exchange PR Newswire

Aug 22, 2021

05:21AM EDT PLX: Debt Maturities Resolved Benzinga

Aug 16, 2021

06:58AM EDT Protalix BioTherapeutics Q2 Net Loss $11.2 Mln Or $0.25/Shr Vs Loss Of $4.2 Mln Or $0.13/Shr Last Year RTTNews

06:51AM EDT Protalix BioTherapeutics Q2 EPS $(0.25) Down From $(0.13) YoY Benzinga

06:50AM EDT Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and PR Newswire

04:04AM EDT Earnings Scheduled For August 16, 2021 Benzinga

Aug 13, 2021

06:50AM EDT Protalix BioTherapeutics Announces Private Note Exchange PR Newswire

Aug 9, 2021

07:15AM EDT Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and PR Newswire

Aug 2, 2021

08:03AM EDT Protalix Stock Is Trading Higher On Meeting Request To FDA For Fabry Disease Candidate Application Benzinga

06:52AM EDT Protalix BioTherapeutics Announces Submission Of Type A Meeting Request To The FDA To Discuss CRL For PRX-102 Biologics License Application Benzinga

06:51AM EDT Protalix BioTherapeutics Announces Submission Of Type A Meeting Request To FDA For Pegunigalsidase Alfa RTTNews

06:50AM EDT Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the PR Newswire

Jun 28, 2021

06:50AM EDT Protalix BioTherapeutics to Participate in a Fireside Chat on June 30, 2021 PR Newswire

Jun 8, 2021

09:41AM EDT PLX: BALANCE: Interim Results Benzinga

Jun 7, 2021

10:18PM EDT Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. (Protalix or the Company) (NYSE:PLX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Jun 2, 2021

02:39PM EDT Mid-Afternoon Market Update: Constellation Pharmaceuticals Surges Following Acquisition News; Protalix BioTherapeutics Shares Slide Benzinga

12:30PM EDT Mid-Day Market Update: Crude Oil Rises 1%; iRhythm Technologies Shares Plunge Benzinga

12:11PM EDT Protalix Shares Hits 52-Week Low After Adverse Event Reported In Fabry Disease Trial With PRX-102 Benzinga

08:02AM EDT Protalix, Chiesi Global Announce Topline Results From The RTTNews

06:54AM EDT Protalix, Chiesi Global Announce Topline Results From Interim Analysis Of Phase III BALANCE Clinical Trial RTTNews

06:51AM EDT Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease Benzinga

06:50AM EDT Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease PR Newswire

May 30, 2021

07:21AM EDT PLX: 1Q:21 Results & Next Steps Benzinga

May 20, 2021

12:25PM EDT Looking Into Protalix BioTherapeutics's Return On Capital Employed Benzinga

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

06:53AM EDT Protalix BioTherapeutics Q1 Loss/Shr $0.14 Vs EPS $0.10 Last Year RTTNews

06:51AM EDT Protalix BioTherapeutics Q1 EPS $(0.14) Beats $(0.17) Estimate, Sales $11.32M Beat $10.95M Estimate Benzinga

06:50AM EDT Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and PR Newswire

04:03AM EDT Earnings Scheduled For May 14, 2021 Benzinga

May 13, 2021

12:45PM EDT Earnings Preview for Protalix BioTherapeutics Benzinga

May 7, 2021

10:30AM EDT Protalix BioTherapeutics to Hold First Quarter 2021 Financial and Business PR Newswire

May 4, 2021

06:21AM EDT PLX: Pandemic Backup Impedes FDA Site Survey Benzinga

May 3, 2021

03:45PM EDT Protalix BioTherapeutics shares were trading higher after HC Wainwright & Co maintained a Buy rating on the stock. Benzinga

07:37AM EDT HC Wainwright & Co. Maintains Buy on Protalix BioTherapeutics, Lowers Price Target to $7 Benzinga

Apr 28, 2021

02:37PM EDT Mid-Afternoon Market Update: Dow Drops 90 Points; Fed Leaves Rates Unchanged Benzinga

01:29PM EDT Protalix BioTherapeutics Provides Update on Complete Response Letter for PR Newswire

12:20PM EDT Mid-Day Market Update: Crude Oil Rises 2%; Protalix BioTherapeutics Shares Plunge Benzinga

10:25AM EDT Mid-Morning Market Update: Markets Mixed; Alphabet Tops Q1 Expectations Benzinga

07:26AM EDT The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping Benzinga

06:21AM EDT Protalix Stock Falls After FDA Slaps CRL For PRX-102 Application In Fabry Disease Benzinga

05:36AM EDT Protalix BioTherapeutics and Chiesi Global Rare Diseases Announced Complete Response Letter for Pegunigalsidase Alfa as Treatment for Fabry Disease from FDA Benzinga

02:08AM EDT Protalix Receives Complete Response Letter Regarding BLA RTTNews

01:52AM EDT Protalix BioTherapeutics And Chiesi Global Rare Diseases Receive CRL For Pegunigalsidase Alfa From FDA RTTNews

01:51AM EDT Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete PR Newswire

Apr 27, 2021

07:41AM EDT The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout Benzinga

Apr 24, 2021

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

Mar 30, 2021

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

06:53AM EDT Protalix BioTherapeutics FY20 Net Loss $6.5 Mln Or $0.22/Shr Vs Loss $18.3 Mln Or $1.23/Shr Last Year RTTNews

06:51AM EDT Protalix BioTherapeutics FY20 Sales $62.9M, Up From $54.69M YoY EPS $(0.22), Up From $(1.23) YoY Benzinga

06:51AM EDT Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results PR Newswire

04:04AM EDT Earnings Scheduled For March 30, 2021 Benzinga

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 22, 2021

06:50AM EDT Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business PR Newswire

Mar 4, 2021

06:50AM EST Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences PR Newswire

Feb 23, 2021

08:04AM EST Protalix's PRX102 Monthly Treatment Shows Benefit In Fabry Disease Benzinga

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

06:53AM EST Protalix BioTherapeutics And Chiesi Global Rare Diseases Announce Positive Topline Results From BRIGHT Phase III Trial RTTNews

06:52AM EST Protalix BioTherapeutics and Chiesi Global Rare Diseases Announces Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Achieved Key Objectives For Safety, Efficacy, And Pharmacokinetics Benzinga

06:50AM EST Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease PR Newswire

Feb 18, 2021

08:04AM EST Protalix BioTherapeutics Completes Raise Of About $40 Mln In Gross Proceeds RTTNews

08:03AM EST Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross PR Newswire

Feb 12, 2021

05:54AM EST Protalix BioTherapeutics Raises $35M Via Equity At 21% Discount Benzinga

Feb 11, 2021

09:21PM EST Protalix BioTherapeutics Prices Public Offering Of 7.61 Mln Shares At $4.60/shr RTTNews

09:17PM EST Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of PR Newswire

04:36PM EST Protalix BioTherapeutics Announces Proposed 6.5M Share Common Stock Offering Benzinga

04:36PM EST Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock PR Newswire

06:52AM EST Protalix Partners With SarcoMed To Develop Alidornase Alfa For Pulmonary Sarcoidosis And Respiratory Diseases RTTNews

06:50AM EST to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery PR Newswire

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

07:02AM EST Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium(tm) 2021 PR Newswire

Feb 6, 2021

12:42PM EST The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight Benzinga

Feb 1, 2021

06:50AM EST Protalix BioTherapeutics Announces Presentations at the 17th Annual PR Newswire

Jan 9, 2021

04:41AM EST PLX: Final Results for BRIDGE and A Letter to Shareholders Benzinga

Jan 4, 2021

06:50AM EST Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in PR Newswire

Dec 30, 2020

07:14AM EST Protalix BioTherapeutics, Inc. (PLX), a biopharmaceutical company, said Wednesday that its President and Chief Executive Officer Dror Bashan has sent an annual letter to the company's shareholders and the investment community. RTTNews

06:57AM EST Pritalix BioTherapeutics Issues A Letter To Shareholders Reflecting On Transformation On Its Accomplishments In 2020 A Submission To The FDA For Its Biologics License Application For PRX-102 Dor The Treatment Of Adults With Fabry Disease Benzinga

06:53AM EST Protalix BioTherapeutics Says Continued To Seek Multiple Collaborative Partnerships To Complement Core Platform RTTNews

06:50AM EST Protalix BioTherapeutics Issues 2020 Letter to Shareholders PR Newswire

06:22AM EST Protalix & Chiesi: Phase III BRIDGE Trial Evaluating RTTNews

06:14AM EST Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce The Final Results For Its BRIDGE Phase 3 Open-Label Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease Benzinga

06:04AM EST Protalix, Chiesi Global Rare Diseases Announce Final Results Of BRIDGE Phase III Trial Of Pegunigalsidase Alfa RTTNews

06:01AM EST of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease PR Newswire

Nov 27, 2020

07:04AM EST Protalix: FDA Extends PDUFA Action Date For RTTNews

06:57AM EST Protalix, Chiesi Global Rare Diseases Announce Extension Of PDUFA Date For Pegunigalsidase Alfa To April 27, 2021 RTTNews

06:50AM EST PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease PR Newswire

06:50AM EST Protalix Reports Extension Of PDUFA Date For Pegunigalsidase Alfa For Proposed Treatment Of Fabry Disease By 3 Months From Jan. 27, 2021 To Apr. 27, 2021 Benzinga

Nov 5, 2020

06:50AM EST Protalix BioTherapeutics to Present at the H.C. Wainwright 6th Annual Israel PR Newswire

Oct 29, 2020

01:34PM EDT Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and PR Newswire

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

07:14AM EDT Protalix BioTherapeutics Q3 EPS $(0.14) Beats $(0.17) Estimate, Sales $10.79M Beat $10.08M Estimate Benzinga

06:52AM EDT Protalix BioTherapeutics Q3 Loss Per Share $0.14 Vs Loss $0.24 Last Year RTTNews

06:50AM EDT Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and PR Newswire

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Oct 26, 2020

06:50AM EDT Protalix BioTherapeutics to Participate in Virtual Investor KOL Roundtable PR Newswire

Oct 22, 2020

06:50AM EDT Protalix BioTherapeutics to Hold Third Quarter 2020 Financial Results and PR Newswire

Oct 2, 2020

08:13AM EDT Chiesi Global Rare Diseases And Protalix BioTherapeutics Announce Expanded Access Program For Pegunigalsidase Alfa RTTNews

08:08AM EDT Chiesi Global Rare Disease, Protalix Highlight Launch Of Expanded Access Program In US For Pegunigalsidase Alfa For Proposed Treatment Of Fabry Disease Benzinga

08:03AM EDT Chiesi Global Rare Diseases, Protalix BioTherapeutics Launch Of An EAP In US For Pegunigalsidase Alfa For Fabry Disease RTTNews

08:01AM EDT Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease PR Newswire

08:00AM EDT Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce GlobeNewswire Inc

Sep 8, 2020

07:03AM EDT Protalix Regains Compliance With NYSE American Continued Listing Standards RTTNews

06:55AM EDT Protalix BioTherapeutics Regains Compliance with NYSE American Continued PR Newswire

06:45AM EDT Protalix BioTherapeutics to Present in the H.C. Wainwright 22nd Annual Global PR Newswire

Aug 24, 2020

06:54AM EDT Protalix Completes Treatment Period For Phase III BRIGHT Trial Of Pegunigalsidase Alfa For Treatment Of Fabry Disease RTTNews

06:54AM EDT Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease, Expects to Announce Top-Line Results in Q4 Benzinga

06:50AM EDT Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the Proposed Treatment of Fabry Disease PR Newswire

Aug 11, 2020

06:52AM EDT Protalix BioTherapeutics, Chiesi Announce FDA Acceptance Of BLA For Pegunigalsidase Alfa RTTNews

06:51AM EDT Protalix BioTherapeutics And Chiesi Global Rare Diseases Announce FDA Acceptance Of Biologics License Application For Pegunigalsidase Alfa For The Proposed Treatment Of Fabry Disease And Grants Priority Review Benzinga

06:50AM EDT Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review PR Newswire

Aug 10, 2020

06:58AM EDT Protalix BioTherapeutics Q2 EPS $(1.01) Misses $(0.20) Estimate, Sales $10.97M Beat $10.87M Estimate Benzinga

06:52AM EDT Protalix BioTherapeutics Q2 Loss Per Share $0.13 Vs Loss $0.52 Last Year RTTNews

06:51AM EDT Protalix BioTherapeutics Reports Second Quarter 2020 Financial Results and PR Newswire

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 6, 2020

01:03PM EDT Protalix BioTherapeutics to Present at the BTIG Virtual Biotechnology PR Newswire

Aug 3, 2020

09:14AM EDT Protalix BioTherapeutics to Hold Second Quarter 2020 Financial Results and PR Newswire

Jul 23, 2020

02:32PM EDT Protalix reports Non-Binding Term Sheet With SarcoMed To Develop Alidornase Alfa For Treatment Of Pulmonary Sarcoidosis, Related Diseases Benzinga

02:30PM EDT to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Diseases PR Newswire